News Releases

News and information from The Leukemia & Lymphoma Society

New Research: Americans of Every Political Stripe are Unified in Support of Vice President Biden’s Moonshot to End Cancer

Rye Brook, NY, June 1, 2016 – While divisiveness rules many issues, there is strong agreement among Americans of different political persuasions when it comes to investing in the fight against cancer.  According to a new survey, Finding Cancer Cures, there is widespread support for the Moonshot to End Cancer initiative President Obama launched this year, as 82 percent of Americans polled want the next presiden...

Subaru and LLS Celebrate Gestures of Hope for Subaru Love Promise

Rye Brook, NY (May 31, 2016) – Subaru of America and The Leukemia & Lymphoma Society (LLS) announced a collaboration to provide much needed support and “warmth” to patients fighting cancer and their families in communities across the country.  During Subaru Loves to Care month this June, LLS and participating Subaru retailers across the country together will provide blankets and messages of hope to ...

LLS Applauds Approval of New Therapy for CLL Patients

Rye Brook, NY – April 12, 2016 – The approval of a new therapy for patients with a high-risk form of chronic lymphocytic leukemia (CLL) is welcome news for patients for whom there have been few other options, The Leukemia & Lymphoma Society (LLS) said today. The U.S. Food and Drug Administration has approved venetoclax (Venclexta ®) to treat patients with a rare subset of CLL in which a piece of chromosom...

LLS Recognizes Volunteers During National Volunteer Week

Rye Brook, NY, April 11, 2016 – Volunteer led, staff driven. As the world’s leading voluntary non-profit fighting blood cancers, The Leukemia & Lymphoma Society (LLS) has set the bar in defining volunteerism and demonstrating impact. During National Volunteer Week, April 10-16, 2016, LLS would like to thank all its volunteers making an impact in advocacy, policy and patient access.   “LLS has millio...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: